Clarus Therapeutics Holdings, Inc. Common Stock
CRXT
CRXT was delisted on the 30th of August, 2022.
25 hedge funds and large institutions have $1.82M invested in Clarus Therapeutics Holdings, Inc. Common Stock in 2022 Q2 according to their latest regulatory filings, with 13 funds opening new positions, 8 increasing their positions, 3 reducing their positions, and 1 closing their positions.
1,200% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 1
167% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 3
92% more funds holding
Funds holding: 13 → 25 (+12)
51% less capital invested
Capital invested by funds: $3.73M → $1.82M (-$1.91M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$605K |
| 2 |
BlackRock
New York
|
+$227K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$187K |
| 4 |
SM
Sabby Management
Miami Beach,
Florida
|
+$140K |
| 5 |
VF
Virtu Financial
New York
|
+$117K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$31.5K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$30.1K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
-$2.32K |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$1K |
CRXT Hedge Fund Activity: Q2 2022 in Review
25 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Clarus Therapeutics Holdings, Inc. Common Stock (CRXT) for Q2 2022, worth a combined $1.82M — down 51% from $3.73M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new CRXT positions and 1 closed out — a net gain of 12 holders — while 8 added to existing stakes and 3 trimmed.
The largest buyer was Vanguard Group, adding an estimated $605K. The largest seller was Bridgeway Capital Management, cutting an estimated $31.5K.
- 25 institutional investors held Clarus Therapeutics Holdings, Inc. Common Stock (CRXT) as of Q2 2022, up from 13 in Q1 2022.
- Funds reported $1.82M of Clarus Therapeutics Holdings, Inc. Common Stock stock for Q2 2022, down 51% quarter-over-quarter.
- 13 funds opened new Clarus Therapeutics Holdings, Inc. Common Stock positions in Q2 2022 and 1 closed out, a net change of +12 holders.
- The largest Clarus Therapeutics Holdings, Inc. Common Stock buyer in Q2 2022 was Vanguard Group, an estimated $605K added.
- The largest Clarus Therapeutics Holdings, Inc. Common Stock seller in Q2 2022 was Bridgeway Capital Management, an estimated $31.5K sold.
Based on aggregated 13F filings for Q2 2022.